modelA10AE05
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | InsulinDetemir | |
| ATC code: | A10AE05 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 0.4 | mg |
| volume of distribution: | 0.07 | L |
| clearance: | 0.028 | L/h/kg |
| other parameters in model implementation | ||
Insulin detemir is a long-acting human insulin analogue used for the treatment of diabetes mellitus in adults, adolescents, and children aged 1 year and above. It provides basal insulin coverage to help control blood glucose levels and is approved for use in most countries worldwide.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy subjects and patients with type 1 diabetes; parameters predominantly from subcutaneous administration in adult males and females.
References
Jhee, SS, et al., & Jacobsen, LV (2004). Similarity of insulin detemir pharmacokinetics, safety, and tolerability profiles in healthy caucasian and Japanese american subjects. Journal of clinical pharmacology 44(3) 258–264. DOI:10.1177/0091270003262949 PUBMED:https://pubmed.ncbi.nlm.nih.gov/14973299
Rendell, M (2013). Insulin degludec: a long-acting modern insulin analogue with a predictable pharmacokinetic/pharmacodynamic profile. Drugs of today (Barcelona, Spain : 1998) 49(6) 387–397. DOI:10.1358/dot.2013.49.6.1976051 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23807942
Danne, T, et al., & Kordonouri, O (2008). Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Pediatric diabetes 9(6) 554–560. DOI:10.1111/j.1399-5448.2008.00443.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/18761644
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)